Independent prognostic factors for response: Updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC)

Category Primary study
JournalEuropean Journal of Cancer, Supplement
Year 2010
This article has no abstract
Epistemonikos ID: 3de87e2fa600f86003ee02e858cd15edf49be656
First added on: Feb 28, 2025